Unlocking Substrate Reduction Therapy for Fabry Disease and Shiga Toxin Neutralization. Market Intelligence, Clinical Progress, and High-Purity Reagents for Glycosphingolipid Metabolism Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for A4GALT (Gb3 Synthase) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | A4GALT Catalytic Domain Protein HEK293 Expressed, Sequence Verified, High Purity (>95%), Endotoxin <1EU/µg. Preserves native glycosylation critical for enzymatic stability. |
View A4GALT Products |
| Gene Delivery | A4GALT Lentivirus Premade Particles Full-length ORF with Golgi-targeting domain for stable cell line construction. High titer (>10^8 TU/mL). |
View A4GALT Products |
| Detection Antibody | Anti-A4GALT Recombinant Antibody Sequence-defined monoclonal for Western Blot and Immunofluorescence validation. |
View A4GALT Products |
| Validator | A4GALT siRNA Set (3 unique sequences) For specific knockdown and Gb3 reduction validation assays. |
View A4GALT Products |
| Related Target: GLA | Alpha-Galactosidase A (Deficient in Fabry) Enzymatic counterpart; ERT benchmark enzyme for combination studies. |
View GLA Products |
| Related Target: UGCG | Glucosylceramide Synthase (Upstream) Alternative SRT target; pathway synergy analysis for dual inhibition strategies. |
View UGCG Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Golgi Membrane Mimicry (Lipid-dependent Activity) | Detergent-free purification protocols available; Lipid reconstitution-compatible protein format. |
| Selectivity vs. A4GNT (Alpha-1,4-N-acetylglucosaminyltransferase) | Sequence Verified proteins with strict mass spec confirmation; Homology panel available for counter-screening. |
| Cellular Gb3 Quantification | Lentivirus for stable A4GALT-overexpressing HEK293/CHO lines; Compatible with flow cytometry (Anti-Gb3 antibody co-staining). |
| Substrate Reduction Confirmation | Validated siRNA included for specificity controls; Quantitative knockdown at mRNA level (>70% efficiency). |
Live A4GALT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Fabry Disease Trials (A4GALT/SRT Focus)
- ➤ Latest Shiga Toxin Resistance Research
- ➤ Recent Patent Filings (Gb3 Synthesis Inhibition)
Global Clinical Landscape & Future Outlook
The race for next-generation Fabry disease therapeutics is pivoting from sole reliance on Enzyme Replacement Therapy (ERT) toward oral Substrate Reduction Therapies (SRT) targeting A4GALT. As the synthetic gateway to globotriaosylceramide (Gb3), A4GALT inhibition offers the potential to reduce substrate accumulation at its source, addressing neuropathic pain and delaying renal failure with improved patient compliance compared to bi-weekly infusions. Simultaneously, the antimicrobial drug discovery sector is exploring A4GALT inhibitors as host-directed therapeutics against Shiga toxin-producing E. coli (STEC), preventing Hemolytic Uremic Syndrome (HUS) by eliminating the Gb3 receptor.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule SRT | Idorsia, Takeda, Sanofi | Fabry Disease | High-throughput Enzymatic Assay (Need purified catalytic domain); Lipid substrate compatibility. |
| Antisense Oligonucleotides | Ionis Pharmaceuticals (Pipeline) | Familial Amyloidosis / Gb3-related | Cell-based Knockdown Validation (Need siRNA controls and lentivirus delivery systems). |
| Host-Directed Anti-Infective | Academic Consortia, DARPA-funded | STEC-HUS Prevention | Gb3 Surface Expression Assay (Need stable cell lines via lentivirus). |
| Gene Therapy (ERT Adjunct) | AVROBIO, Orchard Therapeutics | Classic Fabry (GLA deficiency) | Pathway Analysis Tools (Need both GLA and A4GALT proteins for mechanistic studies). |